SEC Form 4
Biogen Inc. (BIIB) insider trading
In the 12 months to Oct 24, 2026, 2 BIIB insiders reported open-market sales of $905.4K across 3 filings; one head of pharm ops and tech bought $585.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $905.4K
- 3 filings · 2 insiders
- Open-market purchases
- $585
- 1 filing · Nicole Murphy, Head of Pharm Ops and Tech
- Pre-arranged sales (10b5-1)
- 3 of 3
- All $905.4K sold was pre-arranged
Who traded BIIB, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
BIIB daily close from Oct 24, 2025 to Oct 23, 2026, between $147.86 and $253.84, last $250.69. 3 sale and 1 purchase filings by 3 insiders, marked at their filing dates. Priya Singhal, Head of Development: sold $665.7K across 2 filings, first filed Feb 3, 2026, last Feb 10, 2026. Lloyd Minor, Director: sold $239.7K across 1 filing, first filed Aug 5, 2026, last Aug 5, 2026. Nicole Murphy, Head of Pharm Ops and Tech: bought $585 across 1 filing, first filed Feb 17, 2026, last Feb 17, 2026.
Largest mark · tap a row for others
Priya Singhal · Head of Development
Sale $531,548
2,660 shares at $199.83 avg
Filed Feb 10, 2026 · traded Feb 9
Pre-arranged (10b5-1) · close on filing date $188.99
Priya Singhal · Head of Development
Head of Development
$665.7K soldLloyd Minor · Director
Director
$239.7K soldNicole Murphy · Head of Pharm Ops and Tech
Head of Pharm Ops and Tech
$585 boughtHas Biogen Inc.'s CEO sold stock?
No. Christopher Viehbacher (CEO) made no open-market sales filed as CEO in the last 12 months.
Open-market trades
4 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Priya Singhal | Head of Development | $665.7K | — | 2 | 100% of sales | |
| Lloyd Minor | Director | $239.7K | — | 1 | 100% of sales | |
| Nicole Murphy | Head of Pharm Ops and Tech | — | $585 | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Lloyd Minor Director | SalePre-arranged (10b5-1) | 1,186 | $202.15 | $239.7K | 2,689 | |
traded | Nicole Murphy Head of Pharm Ops and Tech | Purchase | 3 | $195.04 | $585 | 19,611 | |
traded | Priya Singhal Head of Development | SalePre-arranged (10b5-1) | 2,660 | $199.83 | $531.5K | 8,043 | |
traded | Priya Singhal Head of Development | SalePre-arranged (10b5-1) | 748 | $179.30 | $134.1K | 6,271 |
GET /stocks/filings/vX/form-4?tickers=BIIB&filing_date.gte=2025-10-24&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"BIIB"
],
"issuer_cik": "0000875045",
"owner_cik": "0002038687",
"accession_number": "0000875045-26-000076",
"form_type": "4",
"filing_date": "2026-08-05",
"period_of_report": "2026-08-03",
"issuer_name": "BIOGEN INC.",
"issuer_trading_symbol": "BIIB",
"owner_name": "Minor Lloyd",
"is_director": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-08-04",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 593,
"transaction_price_per_share": 200.96,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 2689,
"transaction_value": 119169.28,
"direct_or_indirect": "D"
},
{
"tickers": [
"BIIB"
],
"issuer_cik": "0000875045",
"owner_cik": "0002038687",
"accession_number": "0000875045-26-000076",
"form_type": "4",
"filing_date": "2026-08-05",
"period_of_report": "2026-08-03",
"issuer_name": "BIOGEN INC.",
"issuer_trading_symbol": "BIIB",
"owner_name": "Minor Lloyd",
"is_director": true,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-08-03",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 593,
"transaction_price_per_share": 203.34,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 3282,
"transaction_value": 120580.62,
"direct_or_indirect": "D"
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 74 records
- Option exercises33 records
- Tax withholding32 records
- Grants and awards9 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
Build this yourself
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for BIIB every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.